Abstract:WAG/Rij rats are a valid model of absence epilepsy and comorbid depression. We have previously shown that WAG/Rij rats have disturbances in the sleep–wake cycle and changes in the characteristics of sleep spindles. A negative correlation was also found between the number of spike-wave discharges (SWD) and the duration of rapid eye movement (REM) sleep. Clinical evidence suggests that the traditional antidepressants imipramine and fluoxetine are effective in suppressing symptoms of depression, but may have a negative impact on the sleep–wake cycle and comorbid epilepsy in patients. Our previous studies in WAG/Rij rats showed that imipramine, when administered chronically, increases the number of SWDs, while fluoxetine at the same dose reduces their number, although both antidepressants have a pronounced antidepressant effect. Comparison of the effects of the antidepressants imipramine and fluoxetine on the sleep–wake cycle and sleep spindles in WAG/Rij rats remains unstudied. The purpose of this work is to find out: (1) what effects do imipramine and fluoxetine have on the sleep–wake cycle and the characteristics of sleep spindles in WAG/Rij rats and (2) whether there are differences in their effects. To achieve this goal, the characteristics of the sleep–wake cycle and sleep spindles were compared in WAG/Rij rats after chronic administration of antidepressants and saline and in non-epileptic Wistar rats. Administration of imipramine led to a significant decrease in the duration of REM sleep. The administration of imipramine, compared with fluoxetine, also increased the latency of the transition to sleep and the transition to REM sleep. Sleep spindle amplitude was significantly increased by both antidepressants. However, the spectral power density of "slow" and "medium" spindles, which predominate in WAG/Rij rats compared to Wistar rats, was significantly higher after administration of imipramine than fluoxetine. The results suggest that imipramine causes greater negative changes in the sleep–wake cycle and sleep spindles than fluoxetine. Studies in the WAG/Rij rat model indicate that fluoxetine is more preferable antidepressant for the treatment of depressive disorders comorbid with absence epilepsy, since it does not cause a significant deterioration in sleep quality. These results are consistent with clinical data.

Fluoxetine accelerates epileptogenesis and magnifies disease severity in a rat model of acquired epilepsy

PET imaging identifies anti-inflammatory effects of fluoxetine and a correlation of glucose metabolism during epileptogenesis with chronic seizure frequency

Fluoxetine Can Cause Epileptogenesis and Aberrant Neurogenesis in Male Wild-Type Mice

Chronic Fluoxetine Enhances Extinction Therapy for PTSD by Evaluating Brain Glucose Metabolism in Rats: an [18F]FDG PET Study

Fluoxetine inhibition of glycine receptor activity in rat hippocampal neurons

A Two-Hit Approach Inducing Flurothyl Seizures in Fmr1 Knockout Mice Impacts Anxiety and Repetitive Behaviors

Juvenile fluoxetine treatment affects the maturation of the medial prefrontal cortex and behavior of adolescent female rats

Fluoxetine increases the activity of the ERK-CREB signal system and alleviates the depressive-like behavior in rats exposed to chronic forced swim stress.

Fluoxetine induces input-specific hippocampal dendritic spine remodeling along the septotemporal axis in adulthood and middle age

Maternal fluoxetine impairs synaptic transmission and plasticity in the medial prefrontal cortex and alters the structure and function of dorsal raphe nucleus neurons in offspring mice

Chronic treatment with fluoxetine downregulates mitochondrial activity in parvalbumin interneurons of prefrontal cortex

The impact of chronic fluoxetine treatment in adolescence or adulthood on context fear memory and perineuronal nets

Alleviative Effects of Fluoxetine on Depressive-Like Behaviors by Epigenetic Regulation of BDNF Gene Transcription in Mouse Model of Post-Stroke Depression

Chronic Fluoxetine Treatment Reverses Depressive-like Behaviors in Mice via Enhancing Neuroplasticity

Fluoxetine Mitigating Late-Stage Cognition and Neurobehavior Impairment Induced by Cerebral Ischemia Reperfusion Injury Through Inhibiting ERS-mediated Neurons Apoptosis in the Hippocampus

Fluoxetine Potentiates GABAergic IPSCs in Rat Hippocampal Neurons.

Fluoxetine Exposure for More Than 2 Days Decreases the Neuronal Plasticity Mediated by CRMP2 in Differentiated PC12 Cells

The effects of maternal SSRI exposure on the serotonin system, prefrontal protein expression and behavioral development in male and female offspring rats

Behavioral and neurotransmitter changes on antiepileptic drugs treatment in the zebrafish pentylenetetrazol-induced seizure model

Fluoxetine upregulates phosphorylated-AKT and phosphorylated-ERK1/2 proteins in neural stem cells: evidence for a crosstalk between AKT and ERK1/2 pathways

Comparison of the Effect of the Antidepressants Imipramine and Fluoxetine on the Sleep–Wake Cycle and Characteristics of Sleep Spindles in Wag/Rij Rats with Absence Epilepsy and Comorbid Depression